You are here

dwarfism

BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment Results

Investors Business Daily

Tue, 06/4/24 - 11:42 am

JPM24: BioMarin's new CEO Hardy says top priority is expansion of dwarfism drug Voxzogo

Fierce Pharma

Wed, 01/10/24 - 11:43 am

Alexander Hardy

BridgeBio Soars 64% And Breaks Out After Smashing Expectations In A Dwarfism Study

Investors Business Daily

Mon, 03/6/23 - 11:09 am

FDA approves first drug for genetic cause of dwarfism

Stat

Fri, 11/19/21 - 11:06 am

BioMarin's new launch Voxzogo could surprise investors and become a blockbuster brand: analyst

Fierce Pharma

Mon, 11/15/21 - 12:24 pm

BioMarin stands tall with first approved drug for rare disease that causes dwarfism

MedCity News

Sat, 08/28/21 - 08:57 pm

After scoring big Pfizer buyout, a Therachon co-founder turns once again to dwarfism with $24M Series A

Endpoints

Mon, 12/14/20 - 10:31 am

BioMarin nabs FDA review for dwarfism drug vosoritide, forgoes AdComm as it eyes 2021 approval

Fierce Biotech

Wed, 11/4/20 - 10:57 pm

BioMarin (BMRN) Files NDA for Vosoritide to Treat Dwarfism

Yahoo/Zacks.com

Fri, 08/21/20 - 11:56 am

Cancer drug to treat dwarfism? Abandoned Novartis asset snagged by BridgeBio’s QED Therapeutics

Endpoints

Wed, 01/31/18 - 09:20 am

BioMarin shines as dwarfism drug boosts growth in children

Fierce Biotech

Thu, 06/18/15 - 10:28 am

Pipeline Progress at BioMarin

Zacks

Sat, 09/29/12 - 12:36 pm

phenylketonuria